Long-term outcomes of graves disease in children treated with anti-thyroid drugs
| Autor: | Chen-Mei Hung, Hsin-Jung Li, Chia-Jung Chan, Shih-Kang Huang, Chon-In Chan, Yi-Lei Wu, Chi-Yu Huang, Ya-Ting Chiang, Bi-Wen Cheng, Wei-Hsin Ting, Chao-Hsu Lin, Yann-Jinn Lee |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Adolescent Graves' disease Age at diagnosis 030209 endocrinology & metabolism 03 medical and health sciences 0302 clinical medicine children Antithyroid Agents 030225 pediatrics medicine Long term outcomes Effective treatment Humans adolescents Child Retrospective Studies business.industry Optimal treatment Thyroid lcsh:RJ1-570 lcsh:Pediatrics medicine.disease Graves Disease medicine.anatomical_structure Child Preschool Pediatrics Perinatology and Child Health Population study antithyroid drugs Female Remission rate business |
| Zdroj: | Pediatrics and Neonatology, Vol 61, Iss 3, Pp 311-317 (2020) |
| ISSN: | 2212-1692 |
| Popis: | Background: Graves disease (GD) is the most common cause of thyrotoxicosis in children and adolescents, accounting for 15% of all thyroid diseases during childhood. Anti-thyroid drugs (ATD) are recommended as the first-line treatment in children and adolescents. However, the remission rate is lower in children than in adults, and the optimal treatment duration and favorable factors associated with remission remain unknown. We aimed to investigate long-term outcomes of pediatric GD patients receiving ATD. Methods: We retrospectively reviewed medical charts of 396 GD subjects from 1985 to 2017 at MacKay Children's Hospital. Ninety–six patients were excluded from the analyses, including 71 patients followed for less than one year, 6 patients who received radioactive therapy and 19 patients who received surgery. The remaining 300 patients initially treated with ATD and followed up for more than 1 year constituted our study population. Results: The 300 patients comprised 257 (85.7%) females and 43 (14.3%) males. Their median age at diagnosis was 11.6 (range 2.7–17.8) years with 11 patients (3.7%) younger than 5 years. Their median follow-up period was 4.7 (range 1.1–23.9) years. Overall, 122 patients achieved the criteria for discontinuing ATD treatment, and seventy-nine (39.9%) patients achieved remission, with a median follow-up period of 5.3 (range 1.5–20.1) years. Patients in the remission group were more likely to be aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|